8G2M

The tumor activated anti-CTLA-4 monoclonal antibody XTX101 demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

Summary for 8G2M

• Entry DOI: 10.2210/pdb8g2m/pdb
• Descriptor: masking peptide, Heavy chain of humanized IgG, Light chain of humanized IgG, ... (5 entities in total)
• Functional Keywords: engineered antibody, immune system
• Biological source: Mus musculus; More
• Total number of polymer chains: 3
• Total formula weight: 47103.47

Authors

Williams, J.C.,Williams, J.C. (deposition date: 2023-02-05, release date: 2024-02-14, Last modification date: 2024-10-30)

Primary citation

Jenkins, K.A.,Park, M.,Pederzoli-Ribeil, M.,Eskiocak, U.,Johnson, P.,Guzman, W.,McLaughlin, M.,Moore-Lai, D.,O'Toole, C.,Liu, Z.,Nicholson, B.,Flesch, V.,Qiu, H.,Clackson, T.,O'Hagan, R.C.,Rodeck, U.,Karow, M.,O'Neil, J.,Williams, J.C.
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
J Immunother Cancer, 11:-, 2023

PubMed Abstract: The clinical benefit of the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab has been well established but limited by immune-related adverse events, especially when ipilimumab is used in combination with anti-PD-(L)1 mAb therapy. To overcome these limitations, we have developed XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 mAb.

PubMed: 38164757
DOI: 10.1136/jitc-2023-007785

Experimental method

X-RAY DIFFRACTION (1.8 Å)